July 1, 2019, JAMA Internal Medicine released online an article authored by Kitahara et al entitled “Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism.” The Altmetric Attention Score, a global indicator of interest from lay public and colleagues, skyrocketed to 223 by July 7, placing the article in the top 5% of all scored reports. The overall perception of death from cancer risk associated with 131I is inflated and not supported by evidence. As co-authors of this article, we offer previously unpublished data and analysis that (1) disputes clinical significance of the associated risk from 131I and (2) shows, again, that antithyroid drugs carry a statistically significant and a much more obvious cancer death risk.
From the *Section of Nuclear Medicine, Department of Radiology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA
†Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN.
Received for publication July 19, 2019; revision accepted July 22, 2019.
Conflicts of interest and sources of funding: none declared.
Mark Tulchinsky and A. Bertrand Brill have contributed equally to this work.
Correspondence to: Mark Tulchinsky, MD, FSNMMI, FACNP, Section of Nuclear Medicine, Department of Radiology, Penn State Health Milton S. Hershey Medical Center, M.C. H066, 500 University Dr, Hershey, PA 17033. E-mail: Mark.Tulchinsky@gmail.com.
Online date: August 26, 2019